Last reviewed · How we verify

NCT05171322

Using Technical Filtering and Clinical Criteria to Reduce Vital Sign Alarms Using Continuous Monitoring in the Ward

Completed Last updated 14 January 2022
What this trial tests

trial testing WARD in Vital Signs in 850 participants. Completed in 15 January 2021.

Timeline
20 February 2018
Primary endpoint
15 January 2021
15 January 2021

Quick facts

Lead sponsorRigshospitalet, Denmark
StatusCompleted
Study typeOBSERVATIONAL
Enrollment850
Start date20 February 2018
Primary completion15 January 2021
Estimated completion15 January 2021
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Vital Signs. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to describe the extent of vital sign threshold alarm reduction in relation to several simple multilevel minimum duration criteria and artefact removal. We hypothesize that the amount off false alarms will be decreased using different filters.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of WARD

Trials testing the same drug.

Other recruiting trials for Vital Signs

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05171322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing